Cargando…

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination

BBIBP-CorV exerts efficient protection against SARS-CoV-2 infection. However, waning vaccine-induced humoral immune responses after two-dose vaccination have significantly undermined durable immuno-protection. In this study, we have demonstrated that although anti-spike (S) antibody responses in BBI...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Dong, Chen, Yingying, Yu, Xiaoqi, Lai, Yang-dian, Xu, Wenxin, Ji, Ping, Yang, Zhitao, Chen, Erzhen, Zhang, Xinxin, Wang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621266/
https://www.ncbi.nlm.nih.gov/pubmed/36166417
http://dx.doi.org/10.1080/22221751.2022.2130101
_version_ 1784821502103781376
author Wei, Dong
Chen, Yingying
Yu, Xiaoqi
Lai, Yang-dian
Xu, Wenxin
Ji, Ping
Yang, Zhitao
Chen, Erzhen
Zhang, Xinxin
Wang, Ying
author_facet Wei, Dong
Chen, Yingying
Yu, Xiaoqi
Lai, Yang-dian
Xu, Wenxin
Ji, Ping
Yang, Zhitao
Chen, Erzhen
Zhang, Xinxin
Wang, Ying
author_sort Wei, Dong
collection PubMed
description BBIBP-CorV exerts efficient protection against SARS-CoV-2 infection. However, waning vaccine-induced humoral immune responses after two-dose vaccination have significantly undermined durable immuno-protection. In this study, we have demonstrated that although anti-spike (S) antibody responses in BBIBP-CorV vaccinees exhibited three serotypes after 6 months, including de novo sero-negative, sero-positive, and sero-decay features, S-specific interferon-γ release as well as Th1 cytokine production in CD4(+) and CD8(+) T cells were comparable, especially in vaccinees without detectable neutralizing antibodies. Notably, regardless of dramatic increases in humoral immunity after booster vaccination, T cell responses targeting S protein from either wild type or Omicron remained stable before and after booster vaccination in all three serotype vaccinees. No severe cases were observed even in the sero-decay group during the Omicron epidemic in Shanghai. Our results thus illustrate that unlike fluctuating humoral responses, viral-specific T cell responses are extremely stable after booster vaccination. Sustained T cell responses might be dedicated to the rapid restoration of antibody responses after booster vaccination.
format Online
Article
Text
id pubmed-9621266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-96212662022-11-01 Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination Wei, Dong Chen, Yingying Yu, Xiaoqi Lai, Yang-dian Xu, Wenxin Ji, Ping Yang, Zhitao Chen, Erzhen Zhang, Xinxin Wang, Ying Emerg Microbes Infect Coronaviruses BBIBP-CorV exerts efficient protection against SARS-CoV-2 infection. However, waning vaccine-induced humoral immune responses after two-dose vaccination have significantly undermined durable immuno-protection. In this study, we have demonstrated that although anti-spike (S) antibody responses in BBIBP-CorV vaccinees exhibited three serotypes after 6 months, including de novo sero-negative, sero-positive, and sero-decay features, S-specific interferon-γ release as well as Th1 cytokine production in CD4(+) and CD8(+) T cells were comparable, especially in vaccinees without detectable neutralizing antibodies. Notably, regardless of dramatic increases in humoral immunity after booster vaccination, T cell responses targeting S protein from either wild type or Omicron remained stable before and after booster vaccination in all three serotype vaccinees. No severe cases were observed even in the sero-decay group during the Omicron epidemic in Shanghai. Our results thus illustrate that unlike fluctuating humoral responses, viral-specific T cell responses are extremely stable after booster vaccination. Sustained T cell responses might be dedicated to the rapid restoration of antibody responses after booster vaccination. Taylor & Francis 2022-10-26 /pmc/articles/PMC9621266/ /pubmed/36166417 http://dx.doi.org/10.1080/22221751.2022.2130101 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Coronaviruses
Wei, Dong
Chen, Yingying
Yu, Xiaoqi
Lai, Yang-dian
Xu, Wenxin
Ji, Ping
Yang, Zhitao
Chen, Erzhen
Zhang, Xinxin
Wang, Ying
Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
title Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
title_full Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
title_fullStr Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
title_full_unstemmed Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
title_short Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
title_sort comparable antigen-specific t cell responses in vaccinees with diverse humoral immune responses after the primary and booster bbibp-corv vaccination
topic Coronaviruses
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621266/
https://www.ncbi.nlm.nih.gov/pubmed/36166417
http://dx.doi.org/10.1080/22221751.2022.2130101
work_keys_str_mv AT weidong comparableantigenspecifictcellresponsesinvaccineeswithdiversehumoralimmuneresponsesaftertheprimaryandboosterbbibpcorvvaccination
AT chenyingying comparableantigenspecifictcellresponsesinvaccineeswithdiversehumoralimmuneresponsesaftertheprimaryandboosterbbibpcorvvaccination
AT yuxiaoqi comparableantigenspecifictcellresponsesinvaccineeswithdiversehumoralimmuneresponsesaftertheprimaryandboosterbbibpcorvvaccination
AT laiyangdian comparableantigenspecifictcellresponsesinvaccineeswithdiversehumoralimmuneresponsesaftertheprimaryandboosterbbibpcorvvaccination
AT xuwenxin comparableantigenspecifictcellresponsesinvaccineeswithdiversehumoralimmuneresponsesaftertheprimaryandboosterbbibpcorvvaccination
AT jiping comparableantigenspecifictcellresponsesinvaccineeswithdiversehumoralimmuneresponsesaftertheprimaryandboosterbbibpcorvvaccination
AT yangzhitao comparableantigenspecifictcellresponsesinvaccineeswithdiversehumoralimmuneresponsesaftertheprimaryandboosterbbibpcorvvaccination
AT chenerzhen comparableantigenspecifictcellresponsesinvaccineeswithdiversehumoralimmuneresponsesaftertheprimaryandboosterbbibpcorvvaccination
AT zhangxinxin comparableantigenspecifictcellresponsesinvaccineeswithdiversehumoralimmuneresponsesaftertheprimaryandboosterbbibpcorvvaccination
AT wangying comparableantigenspecifictcellresponsesinvaccineeswithdiversehumoralimmuneresponsesaftertheprimaryandboosterbbibpcorvvaccination